» Articles » PMID: 971701

Observations on the Efficacy and Pharmacokinetics of Sotalol After Oral Administration

Overview
Specialty Pharmacology
Date 1976 Mar 22
PMID 971701
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of sotalol after oral administration were measured on the tachycardia induced by strenuous exercise in normal subjects. Plasma sotalol levels were also determined. The oral administration of sotalol (50, 100, 200 and 400 mg) to 6 subjects produced a progressive reduction in the tachycardia induced by severe exercise. This was similar to the effects of 25, 50, 100, 200, 400 and 800 mg given to different subjects. Each increase in sotalol dose produced a successively greater reduction in exercise tachycardia. This did not appear to be maximum even with 800 mg. Oral sotalol was rapidly absorbed and produced peak blood levels in 2 - 3 hours. The plasma levels of sotalol measured 2 hours after the oral administration of 25 to 800 mg showed never more than a six-fold variation between different subject. The half-life of sotalol in plasma was 12.7 +/- SE 1.6 hours. There was a significant correlation between the logarithm of the plasma sotalol concentration and the percentage reduction of exercise heart rate. It is concluded that the oral administration of sotalol either once or twice daily (depending on dose level) will provide satisfactory 24-hour blockade of beta-adrenoceptors.

Citing Articles

Sotalol Treatment may Interfere With Retrieval, Expression, and/or Reconsolidation Processes Thus Disrupting Traumatic Memories in a Post-Traumatic Stress Disorder Mice Model.

Martinho R, Seixas R, Azevedo M, Oliveira A, Serrao P, Moreira-Rodrigues M Front Pharmacol. 2022; 12:809271.

PMID: 35173611 PMC: 8842001. DOI: 10.3389/fphar.2021.809271.


Approach to Management of Premature Ventricular Contractions.

OQuinn M, Mazzella A, Kumar P Curr Treat Options Cardiovasc Med. 2019; 21(10):53.

PMID: 31487007 DOI: 10.1007/s11936-019-0755-y.


Therapeutic drug monitoring of antiarrhythmic drugs.

Jurgens G, Graudal N, Kampmann J Clin Pharmacokinet. 2003; 42(7):647-63.

PMID: 12844326 DOI: 10.2165/00003088-200342070-00004.


Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects.

Deneer V, Lie-A-Huen L, Kingma J, Proost J, Kelder J, Brouwers J Br J Clin Pharmacol. 1998; 45(5):485-90.

PMID: 9643622 PMC: 1873541. DOI: 10.1046/j.1365-2125.1998.00706.x.


Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Fitton A, Sorkin E Drugs. 1993; 46(4):678-719.

PMID: 7506652 DOI: 10.2165/00003495-199346040-00007.


References
1.
Diamond L . Potentiation of bronchomotor responses by beta adrenergic antagonists. J Pharmacol Exp Ther. 1972; 181(3):434-45. View

2.
Lish P, SHELANSKI M, LABUDDE J, Williams W . Inhibition of cardiac chronotropic action of isoproterenol by Sotalol (MJ 1999) in rat, dog and man. Curr Ther Res Clin Exp. 1967; 9(6):311-24. View

3.
Lish P, WEIKEL J, Dungan K . Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1965; 149(2):161-73. View

4.
Carruthers S, Kelly J, McDevitt D, Shanks R . Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther. 1974; 15(5):497-509. DOI: 10.1002/cpt1974155497. View

5.
BODEM G, Chidsey C . Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man. Clin Pharmacol Ther. 1973; 14(1):26-9. DOI: 10.1002/cpt197314126. View